Can analysts provide better guidance to policymakers about the valuation of health effects? This paper argues that valuation questions usually cannot be easily sidestepped by the use of cost-effectiveness analysis. Valuations are implicit in the measures of program outcome that we use, as illustrated by an examination of a policy of maximizing discounted quality-adjusted life-years (QALYs). The paper concludes that surveys focused directly on the questions that health and safety policymakers face could be a most fruitful source of guidance.
John Mendeloff; Measuring Elusive Benefits: On the Value of Health. J Health Polit Policy Law 1 June 1983; 8 (3): 554–580. doi: https://doi.org/10.1215/03616878-8-3-554
Download citation file: